AAI

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 9, 2024

“This quarter, we continued to enroll patients globally across three Phase 2 trials for our two best-in-class checkpoint agonists: ANB032, our BTLA agonist, and rosnilimab, our PD-1 agonist.

Key Points: 
  • “This quarter, we continued to enroll patients globally across three Phase 2 trials for our two best-in-class checkpoint agonists: ANB032, our BTLA agonist, and rosnilimab, our PD-1 agonist.
  • Collaboration revenue was $7.2 million for the three months ended March 31, 2024, compared to $1.4 million for the three months ended March 31, 2023.
  • Research and development expenses were $37.0 million for the three months ended March 31, 2024, compared to $35.0 million for the three months ended March 31, 2023.
  • General and administrative expenses were $12.3 million for the three months ended March 31, 2024, compared to $10.8 million for the three months ended March 31, 2023.

Alpha Sigma Capital Research Releases April Report on ASC AI Index

Retrieved on: 
Thursday, May 9, 2024

Tampa, FL, May 09, 2024 (GLOBE NEWSWIRE) -- Alpha Sigma Capital Research (ASCR), a subsidiary of Alpha Transform Holdings (ATH), a digital asset investment and advisory organization, released the April report on ASC AI Index (AAI).

Key Points: 
  • Tampa, FL, May 09, 2024 (GLOBE NEWSWIRE) -- Alpha Sigma Capital Research (ASCR), a subsidiary of Alpha Transform Holdings (ATH), a digital asset investment and advisory organization, released the April report on ASC AI Index (AAI).
  • AAI tracks the price performance of the top tokens in the AI sector, using a rules-based criteria designed to reflect the landscape of AI tokens.
  • The index includes the top 30 tokens that meet the minimum criteria of market capitalization, daily trading volume, and quality of exchange venues.
  • To receive monthly reports on ASC AI Index to your inbox, subscribe to alphasigmacapitalresearch.substack.com.

Longevity Biotech, Timeline, Leads the Way in Healthy Aging Research with Groundbreaking Clinical Studies

Retrieved on: 
Monday, May 6, 2024

Additionally, the company has partnered on two new clinical trials in collaboration with prestigious research institutions to expand its applications of Mitopure for healthy aging.

Key Points: 
  • Additionally, the company has partnered on two new clinical trials in collaboration with prestigious research institutions to expand its applications of Mitopure for healthy aging.
  • Timeline, backed by Nestlé and L'Oréal Group investments, builds on 15 years of research and multiple clinical studies.
  • "Our mission has always been to pioneer research that unlocks clinically proven interventions to help people stay healthier for longer.
  • These results open a totally new approach to directly impact our immune cells and help restore their functionality during aging."

ThinkCyte Launches New Website and Showcases VisionSortTM at Global Events

Retrieved on: 
Monday, May 6, 2024

TOKYO, May 6, 2024 /PRNewswire/ -- ThinkCyte today announced that it will be presenting at three major international scientific conferences in the first week of May and the launch of its updated website .

Key Points: 
  • TOKYO, May 6, 2024 /PRNewswire/ -- ThinkCyte today announced that it will be presenting at three major international scientific conferences in the first week of May and the launch of its updated website .
  • The events will showcase both internal research and development achievements as well as presentations from VisionSort customers on the application of the platform to advance research and therapeutic development efforts.
  • "A year ago we launched VisionSort and had just been recognized for technology innovation at CYTO, the premiere international cytometry meeting," said Janette Phi, Chief Business Officer at ThinkCyte.
  • For more information about ThinkCyte's upcoming events, visit: https://thinkcyte.com/conferences/ https://doi.org/10.1016/j.stemcr.2023.12.001

Biolexis Therapeutics to Present Late-Breaking Poster at the American Association of Immunologists (AAI) Annual Meeting 2024

Retrieved on: 
Wednesday, May 1, 2024

AMERICAN FORK, Utah, May 1, 2024 /PRNewswire/ -- Biolexis Therapeutics, Inc. a clinical-stage AI-driven biopharmaceutical company, today announced it will present a late-breaking poster at the 2024 American Association of Immunologists (AAI), taking place May 3-7, 2024, in Chicago, IL.

Key Points: 
  • AMERICAN FORK, Utah, May 1, 2024 /PRNewswire/ -- Biolexis Therapeutics, Inc. a clinical-stage AI-driven biopharmaceutical company, today announced it will present a late-breaking poster at the 2024 American Association of Immunologists (AAI), taking place May 3-7, 2024, in Chicago, IL.
  • The conference brings together the top immunology experts for in-depth discussions exploring a wide array of topics, highlighting the latest groundbreaking discoveries in the field.
  • Biolexis' scientific team will be presenting pre-clinical data demonstrating the efficacy of the company's novel PIM1-inhibitor, BLX-0631.
  • AAI poster presentation details are below:

Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

Retrieved on: 
Tuesday, April 23, 2024

WATERTOWN, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced a poster presenting preclinical data characterizing conditionally-activated IL-10 INDUKINE molecules for the treatment of colitis in animal models, a novel approach leveraging its PREDATOR™ protein engineering platform, at IMMUNOLOGYTM 2024, the annual meeting of the American Association of Immunologists (AAI) taking place May 3-7 in Chicago, Illinois.

Key Points: 
  • Prolonged inflammation results in damage to the GI tract.
  • While the exact cause of IBD is unknown, autoimmune and immune-mediated factors have been shown to contribute to the severity of the disease.
  • Results highlighting Werewolf’s findings are summarized in a poster titled, “Development of Conditionally Active IL-10 INDUKINETM Molecules for the Treatment of Inflammatory Bowel Disease” (Board #B906).
  • The poster can be viewed in person on Monday, May 6, 2024, on board number B906, with Werewolf delegates present from 2:15-3:30pm to answer questions.

Alpha Transform Holdings Releases March Report on ASC AI Index

Retrieved on: 
Thursday, April 18, 2024

Tampa, FL, April 18, 2024 (GLOBE NEWSWIRE) -- Alpha Transform Holdings (ATH), a digital asset investment and advisory organization, released the March report on ASC AI Index (AAI).

Key Points: 
  • Tampa, FL, April 18, 2024 (GLOBE NEWSWIRE) -- Alpha Transform Holdings (ATH), a digital asset investment and advisory organization, released the March report on ASC AI Index (AAI).
  • AAI tracks the price performance of the top tokens in the AI sector, using a rules-based criteria designed to reflect the landscape of AI tokens.
  • The index includes the top 30 tokens that meet the minimum criteria of market capitalization, daily trading volume, and quality of exchange venues.
  • To receive monthly reports on ASC AI Index to your inbox, subscribe to alphasigmacapitalresearch.substack.com.

Deepcell Announces Successful Installation of the First Commercial REM-I Platform

Retrieved on: 
Thursday, May 2, 2024

Deepcell , a pioneer in artificial intelligence (AI)-powered single cell analysis to fuel deep biological discoveries, today announced the first commercial placement of the REM-I platform at Erasmus Medical Center in Rotterdam.

Key Points: 
  • Deepcell , a pioneer in artificial intelligence (AI)-powered single cell analysis to fuel deep biological discoveries, today announced the first commercial placement of the REM-I platform at Erasmus Medical Center in Rotterdam.
  • This commercial milestone follows placements of pre-commercial instruments at laboratories in Europe and the U.S. for Beta testing.
  • In addition, the company announced plans to share new data and customer experiences with the REM-I platform at upcoming scientific meetings.
  • “We’ve already seen tremendous interest in the REM-I platform and look forward to sharing more data from our platform at AAI and CYTO."

Parse Biosciences Launches Single Cell Immune Profiling Products

Retrieved on: 
Thursday, May 2, 2024

Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the availability of Evercode™ BCR and the expansion of its existing Evercode™ TCR product line.

Key Points: 
  • Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the availability of Evercode™ BCR and the expansion of its existing Evercode™ TCR product line.
  • The new BCR solution and updates to the existing TCR product line expand Parse’s single cell portfolio and will enable researchers to study the immune repertoire at unprecedented resolution and scale.
  • Evercode BCR allows researchers to capture B cell receptor (BCR) sequences together with gene expression from the same cells.
  • “Scaling up cell counts and sample numbers are crucial for achieving impactful results in single cell immune profiling,” said Parse Biosciences co-founder and CTO Charlie Roco.

NIMML Institute Presents Pioneering Research on Immunometabolic Mechanisms Related to the Pharmacological Activation of LANCL Receptors at Immunology2024, the Annual Meeting of the American Association of Immunologists

Retrieved on: 
Wednesday, April 10, 2024

The AAI meeting will take place at McCormick Place in Chicago, Illinois from May 3 to May 7, 2024.

Key Points: 
  • The AAI meeting will take place at McCormick Place in Chicago, Illinois from May 3 to May 7, 2024.
  • “We are pleased to present our most recent findings related to the immunometabolic mechanisms of activation of LANCL receptors in inflammation & immunology at this year’s AAI Annual Meeting,” said Dr. Josep Bassaganya-Riera, President and Founding Director of NIMML.
  • NImmune’s portfolio includes first and best-in-class omilancor and NIM-1324, two oral, once-daily agonistic therapeutics that bind and activate the LANCL2 pathway.
  • Title: Pharmacological activation of LANCL2 provides immunometabolic support for the restoration of cognitive function markers in a mouse model of Alzheimer’s disease.